Inflection Biosciences
John Lynch has extensive pharmaceutical industry experience, with a 25 year career of achievement in many facets of the industry. His experience covers strategy development, business development, investor relations, product development, sales & marketing and finance. Previously John was CEO at Merrion Pharmaceuticals plc., building the company from a start-up through IPO, completing large licensing deals, fundraisings and other key milestones. Prior to that he held senior commercial roles at Abbott Laboratories in the USA, UK and Ireland. As well as plc and private company Boards, he has served on State Boards, University Boards and on the Irish Government’s Innovation Taskforce.
This person is not in the org chart
This person is not in any offices
Inflection Biosciences
Inflection Biosciences Ltd is an early stage, drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer.